Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

HTSeq—a Python framework to work with high-throughput sequencing data

Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.

Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668

Molecular and cellular insights into T cell exhaustion

Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652

Wnt signalling in stem cells and cancer

Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063

Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function

Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737

The Basic Principles of Chimeric Antigen Receptor Design

Sadelain, M., Brentjens, R. J., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,597

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

Matloubian, M., Concepcion, R. J., & Ahmed, R. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8056-8063.1994 · Cited by 1,162

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,098

Engineered T cells: the promise and challenges of cancer immunotherapy

Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 2×

Systemic Immunity Is Required for Effective Cancer Immunotherapy

Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963

Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells

Klebanoff, C. A., Gattinoni, L., Torabi‐Parizi, P., Kerstann, K. W., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 961

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 947

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898

Human memory T cells: generation, compartmentalization and homeostasis

Farber, D. L., Yudanin, N. A., & Restifo, N. P. (2014) · Nature Reviews Immunology · doi:10.1038/nri3567 · Cited by 897

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 888

Tumor-specific Th17-polarized cells eradicate large established melanoma

Muranski, P. J., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 864

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 822

Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J. R., Wright, C. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 766

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 688

Paths to stemness: building the ultimate antitumour T cell

Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3322 · Cited by 616

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Adusumilli, P. S., Cherkassky, L., Villena‐Vargas, J., Colovos, C., Servais, E. L., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 582

Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection

Crawford, A., Angelosanto, J., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 513

Primary Antitumor Immune Response Mediated by CD4+ T Cells

Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478

Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma

Xie, Y., Akpınarlı, A., Maris, C. H., Hipkiss, E. L., Lane, M. V., Kwon, E. M., Muranski, P. J., Restifo, N. P., & Antony, P. A. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 473

CD4 cells can be more efficient at tumor rejection than CD8 cells

Pérez‐Díez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O. J., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 436

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

de Almeida, L. G. P., Sakabe, N. J., deOliveira, A. R., da Silva, M. C. C., Mundstein, A. S., Cohen, T., Chen, Y., Chua, R., Gurung, S., Gnjatic, S., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn673 · Cited by 436

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

Simon, S., & Labarrière, N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1364828 · Cited by 420

Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells

Kahlon, K. S., Brown, C. E., Cooper, L. J. N., Raubitschek, A. A., Forman, S. J., & Jensen, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0454 · Cited by 369

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 359

Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen

Gay, D. L., Maddon, P. J., Sékaly, R., Talle, M. A., Godfrey, M., Long, E. O., Goldstein, G., Chess, L., Axel, R., Kappler, J. W., et al. (1987) · Nature · doi:10.1038/328626a0 · Cited by 345

CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339

Noncanonical Wnt Signaling Maintains Hematopoietic Stem Cells in the Niche

Sugimura, R., He, X., Venkatraman, A., Arai, F., Box, A., Semerad, C. L., Haug, J. S., Peng, L., Zhong, X.-B., Suda, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.041 · Cited by 306

Insights into Cytokine–Receptor Interactions from Cytokine Engineering

Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma

Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.002 · Cited by 304

Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.

Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R., & Gillespie, G. Y. (1999) · PubMed · Cited by 254

Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells

Brown, C. E., Starr, R., Aguilar, B., Shami, A. F., Martínez, C., D’Apuzzo, M., Barish, M. E., Forman, S. J., & Jensen, M. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1669 · Cited by 227

High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines

Zhao, Y., Bennett, A., Zheng, Z., Wang, Q. J., Robbins, P. F., Yu, L., Li, Y., Molloy, P. E., Dunn, S. M., Jakobsen, B. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5845 · Cited by 221

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

Yang, Y., Kohler, M. E., Chien, C. D., Sauter, C. T., Jacoby, E., Yan, C., Hu, Y., Wanhainen, K., Qin, H., & Fry, T. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1209 · Cited by 208

Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy

Jonnalagadda, M., Mardiros, A., Urak, R. Z., Wang, X., Hoffman, L. J., Bernanke, A., Chang, W.-C., Bretzlaff, W. S., Starr, R., Priceman, S. J., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.208 · Cited by 206

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Scarfò, I., & Maus, M. V. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0230-9 · Cited by 195

Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy

Gattinoni, L., Ji, Y., & Restifo, N. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0356 · Cited by 176

Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy

Thaçi, B., Brown, C. E., Binello, E., Werbaneth, K., Sampath, P., & Sengupta, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou045 · Cited by 175

Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis

Brown, C. E., Warden, C., Starr, R., Deng, X., Badie, B., Yuan, Y., Forman, S. J., & Barish, M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077769 · Cited by 171

Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy

Brown, D. M. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.02.008 · Cited by 168

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

Wang, X., Berger, C., Wong, C. W., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2010) · Blood · doi:10.1182/blood-2010-10-310599 · Cited by 156

Molecular Basis for Shared Cytokine Recognition Revealed in the Structure of an Unusually High Affinity Complex between IL-13 and IL-13Rα2

Lupardus, P. J., Birnbaum, M. E., & García, K. C. (2010) · Structure · doi:10.1016/j.str.2010.01.003 · Cited by 150

Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

Wang, X., Naranjo, A., Brown, C. E., Bautista, C., Wong, C. W., Chang, W.-C., Aguilar, B., Ostberg, J. R., Riddell, S. R., Forman, S. J., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318270dec7 · Cited by 140

Recognition and Killing of Brain Tumor Stem-Like Initiating Cells by CD8+ Cytolytic T Cells

Brown, C. E., Starr, R., Martínez, C., Aguilar, B., D’Apuzzo, M., Todorov, I., Shih, C.-C., Badie, B., Hudecek, M., Riddell, S. R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2687 · Cited by 137

Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response

Rizzuto, G. A., Merghoub, T., Hirschhorn-Cymerman, D., Liu, C., Lesokhin, A. M., Sahawneh, D., Zhong, H., Panageas, K. S., Perales, M., Altan-Bonnet, G. Y., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20081382 · Cited by 113

Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis

Teschner, D., Distler, E., Wehler, D., Frey, M., Marandiuc, D., Langeveld, K., Theobald, M., Thomas, S., & Herr, W. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.114 · Cited by 90

IL-21 Deficiency Influences CD8 T Cell Quality and Recall Responses following an Acute Viral Infection

Yi, J. S., Ingram, J. T., & Zajac, A. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001032 · Cited by 82

Regulated expression of gp130 and IL-6 receptor alpha chain in T cell maturation and activation.

Betz, U. (1998) · International Immunology · doi:10.1093/intimm/10.8.1175 · Cited by 70

Smart CARs engineered for cancer immunotherapy

Priceman, S. J., Forman, S. J., & Brown, C. E. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000232 · Cited by 70

CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study

Touzot, F., Neven, B., Cortivo, L. D., Gabrion, A., Moshous, D., Cros, G., Chomton, M., Luby, J.-M., Terniaux, B., Magalon, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.019 · Cited by 69

MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.

Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Brusić, V., Sidney, J., Sette, A., et al. (2003) · PubMed · Cited by 66

Clonal Abundance of Tumor-Specific CD4 + T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion

Malandro, N., Budhu, S., Kuhn, N. F., Liu, C., Murphy, J. T., Cortez, C. A., Zhong, H., Yang, X., Rizzuto, G. A., Altan-Bonnet, G. Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.12.018 · Cited by 58

Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?

Altomonte, M., Fonsatti, E., Visintin, A., & Maio, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206960 · Cited by 48

Long-term Persistence of CD4+ but Rapid Disappearance of CD8+ T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity

Engels, B., Chervin, A. S., Sant, A. J., Kranz, D. M., & Schreiber, H. W. (2012) · Molecular Therapy · doi:10.1038/mt.2011.286 · Cited by 48

Similar molecular requirements for antigen receptor-triggered secretion of interferon and granule enzymes by cytolytic T lymphocytes

Fortier, A. H., Nacy, C. A., & Sitkovsky, M. V. (1989) · Cellular Immunology · doi:10.1016/0008-8749(89)90112-3 · Cited by 17

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

Tay, R. E., Richardson, E. K., & Toh, H. C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 844

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype

Alizadeh, D., Wong, R. A., Yang, X., Wang, D., Pecoraro, J. R., Kuo, C.-F., Aguilar, B., Qi, Y., Ann, D. K., Starr, R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0466 · Cited by 467

The landscape of the mesenchymal signature in brain tumours

Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 357

Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

Basu, A. B., Ramamoorthi, G., Albert, G. K., Gallen, C., Beyer, A., Snyder, C., Koski, G. K., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 329

198. CD4+ IL13Rα2-Specific CAR T Cells Exhibit Potent Effector Function Against Glioblastoma

Wang, D., Starr, R., Aguilar, B., Brito, A., Chang, B., Sarkissian, A., Badie, B., Barish, M. E., Forman, S. J., & Brown, C. E. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33007-6

Abstract 3024: CD4+ outperform CD8+ central memory-derived CAR T cells, mediating persistent antitumor responses and long-term eradication of glioblastoma

Wang, D., Starr, R., Aguilar, B., Brito, A., Chang, B., Sarkissian, A., Badie, B., Barish, M. E., Forman, S. J., & Brown, C. E. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3024

The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma

Zhai, Y., Li, G., Pan, C., Yu, M., Hu, H., Wang, D., Shi, Z., Jiang, T., & Zhang, W. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217541 · Cited by 33

P06.01 Functional analysis of IL13Rα2-specific chimeric antigen receptor T cells in immunocompetent mouse of glioblastoma

Pituch, K. C., Miska, J. M., Krenciute, G., Li, G., Panek, W. K., Gottschalk, S. M., & Balyasnikova, I. V. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox036.175

CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Prinzing, B. L., Gottschalk, S. M., & Krenciute, G. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1451749 · Cited by 22